India is amongst the most significant medical tourism markets in the world by patient volume, with the Confederation of Indian Industry estimating that the sector generates several billion dollars annually and serves patients from across South Asia, Africa, the Middle East, and increasingly Western countries seeking complex and costly procedures. The country's competitive advantage lies in an extraordinary combination of cost, scale, and specialisation — particularly in cardiac surgery, orthopaedics, oncology, and organ transplantation.
The principal medical tourism corridor runs through Delhi (home to Medanta, Fortis, and Max Healthcare), Mumbai, and Chennai, with Hyderabad emerging as a significant additional hub. These cities host large-volume tertiary hospitals that perform procedures at a scale uncommon in many Western countries, contributing to surgical team experience and outcomes data that bear favourable comparison with international benchmarks. Many senior Indian surgeons have trained at institutions in the United States, United Kingdom, or Australia and hold internationally recognised board certifications.
India has among the highest concentrations of JCI-accredited hospitals outside the United States, reflecting deliberate investment by hospital groups in international quality recognition. The government has actively promoted medical tourism through the Heal in India and Incredible India initiatives, and the dedicated M-class medical visa demonstrates institutional support for the sector.
Despite these strengths, the market is highly heterogeneous. Quality differences between higher-volume accredited facilities and smaller private hospitals can be substantial. International patients are strongly advised to select JCI-accredited or NABH-accredited institutions and to research individual surgeon credentials rather than relying solely on hospital branding.